Strategies to Minimise the Impact of Antimicrobial Treatment on the Selection of Resistant Bacteria

Guide to Antimicrobial Use in Animals

Volumn , Issue , 2009, Pages 77-101

  Lees, Peter ^a   Svendsen, Ove ^b   Wiuff, Camilla ^c  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HEALTH PROTECTION SCOTLAND   (United Kingdom)

Author keywords

Antimicrobial drug pharmacodynamics; Antimicrobial drugs and action mechanism with bacteriostatic or bactericidal agents; Antimicrobial treatment on selection of resistant bacteria; Efficacy breakpoints based on concentration time effect relationships; Mechanisms of selection for resistance; Minimum bactericidal concentration (MBC); Monte Carlo simulations and statistical distribution of selected PK PD index; Pharmacokinetics and pharmacodynamics in antimicrobial chemotherapy; Success (or failure) of antimicrobial prophylaxis, metaphylaxis therapy and assessment criteria

Indexed keywords

EID: 84889372269     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444302639.ch6     Document Type: Chapter

References (124)

1. Wright, G.D. (2005). Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv. Drug Deliv. Rev. 57: 1451-70.
2. Kumar, A. and Schweizer, H.P. (2005). Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv. Drug Deliv. Rev. 57: 1486-1513.
3. Piddock, L.J. (2006). Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19: 382-402.
4. Martinez, J.L. and Baquero, F. (2000). Mutation frequencies and antibiotic resistance. Antimicrob. Agents Chemother. 44: 1771-7.
5. Baquero, F. (2001). Low-level antibiotic resistance. In Andersson, D.H.a.D.I. (ed.), Antibiotic Development and Resistance. Taylor and Francis Group, London, pp. 117-36.
6. Lipsitch, M. and Levin, B.R. (1997). The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41: 363-73.
7. Tenover, F.C. and McGowan, J.E., Jr. (1996). Reasons for the emergence of antibiotic resistance. Am. J. Med. Sci. 311: 9-16.
8. Baquero, F. and Negri, M.C. (1997). Strategies to minimize the development of antibiotic resistance. J. Chemother. 9 Suppl 3: 29-37.
9. Baquero, F., Negri, M.C., Morosini, M.I. and Blazquez, J. (1998). Antibiotic-selective environments. Clin. Infect. Dis. 27 Suppl 1: S5-S11.
10. Negri, M.C., Lipsitch, M., Blazquez, J., Levin, B.R. and Baquero, F. (2000). Concentration dependent selection of small phenotypic differences in TEM beta-lactamasemediated antibiotic resistance. Antimicrob. Agents Chemother. 44: 2485-91.
11. Zhao, X. and Drlica, K. (2001). Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolones studies. Clin. Infect. Dis. 33: S147-S156.
12. Burgess, D.S. (1999). Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 115: 195-233.
13. Baquero, F., Negri, M.C., Morosini, M.I. and Blazquez, J. (1997). The antibiotic selective process: concentrationspecific amplification of low-level resistant populations. CIBA Foundation Symposia, 207: 93-111.
14. Lenski, R.E. (1997). The cost of antibiotic resistance-from the perspective of a bacterium. Ciba Found Symp. 207: 131-140; discussion 141-51.
15. Besier, S., Ludwig, A., Brade, V. and Wichelhaus, T.A. (2005). Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 1426-31.
16. Bjorkman, J., Nagaev, I., Berg, O.G., Hughes, D. and Andersson, D.I. (2000). Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287: 1479-82.
17. Levin, B.R., Perrot, V. and Walker, N. (2000). Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154: 985-97.
18. Maisnier-Patin, S., Berg, O.G., Liljas, L. and Andersson, D.I. (2002). Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol. Microbiol. 46: 355-66.
19. Nagaev, I., Bjorkman, J., Andersson, D.I. and Hughes, D. (2001). Biological cost and compensatory evolution in fusidic acid resistant Staphylococcus aureus. Mol. Microbiol. 40: 433-9.
20. Nilsson, A.I., Kugelberg, E., Berg, O.G. and Andersson, D.I. (2004). Experimental adaptation of Salmonella typhimurium to mice. Genetics 168: 1119-30.
21. Reynolds, M.G. (2000). Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156: 1471-1481.
22. Schrag, S.J., Perrot, V. and Levin, B.R. (1997). Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc. Biol. Sci. 264: 1287-91.
23. Nilsson, A.I., Zorzet, A., Kanth, A., Dahlstrom, S., Berg, O.G. and Andersson, D.I. (2006). Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc. Natl. Acad. Sci. USA 103: 6976-81.
24. Andersson, D.I. (2006). The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol. 9: 461-5.
25. Criswell, D., Tobiason, V.L., Lodmell, J.S. and Samuels, D.S. (2006). Mutations conferring aminoglycoside and spectinomycin resistance in Borrelia burgdorferi. Antimicrob. Agents Chemother. 50: 445-52.
26. Enne, V.I., Delsol, A.A., Davis, G.R., Hayward, S.L., Roe, J.M. and Bennett, P.M. (2005). Assessment of the fitness impacts on Escherichia coli of acquisition of antibiotic resistance genes encoded by different types of genetic element. J. Antimicrob. Chemother. 56: 544-51.
27. Gillespie, S.H., Voelker, L.L. and Dickens, A. (2002). Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb. Drug Resist. 8: 79-84.
28. Ramadhan, A.A. and Hegedus, E. (2005). Survivability of vancomycin resistant enterococci and fitness cost of vancomycin resistance acquisition. J. Clin. Pathol. 58: 744-6.
29. Sander, P., Springer, B., Prammananan, T., et al. (2002). Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob. Agents Chemother. 46: 1204-11.
30. Bjorkman, J., Hughes, D. and Andersson, D.I. (1998). Virulence of antibiotic-resistant Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 95: 3949-53.
31. Cohen, S.P., McMurry, L.M., Hooper, D.C., Wolfson, J.S. and Levy, S.B. (1989). Cross resistance to fluoroquinolones in multiple antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob. Agents Chemother. 33: 1318-25.
32. Giraud, E., Cloeckaert, A., Kerboeuf, D. and Chaslus-Dancla, E. (2000). Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar typhimurium. Antimicrob. Agents Chemother. 44: 1223-8.
33. Kern, W.V., Oethinger, M., Jellen-Ritter, A.S. and Levy, S.B. (2000). Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 44: 814-20.
34. Oethinger, M., Kern, W.V., Jellen-Ritter, A.S., McMurry, L.M. and Levy, S.B. (2000). Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob. Agents Chemother. 44: 10-13.
35. Corkill, J.E., Anson, J.J. and Hart, C.A. (2005). High prevalence of the plasmid-mediated quinolone resistance determinant qnrA in multidrug-resistant Enterobacteriaceae from blood cultures in Liverpool, UK. J. Antimicrob. Chemother. 56: 1115-7.
36. Mammeri, H., Van De Loo, M., Poirel, L., Martinez-Martinez, L. and Nordmann, P. (2005). Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob. Agents Chemother. 49: 71-6.
37. Robicsek, A., Strahilevitz, J., Sahm, D.F., Jacoby, G.A. and Hooper, D.C. (2006). qnr prevalence in ceftazidimeresistant Enterobacteriaceae isolates from the United States. Antimicrob. Agents Chemother. 50: 2872-4.
38. Wang, M., Sahm, D.F., Jacoby, G.A. and Hooper, D.C. (2004). Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob. Agents Chemother. 48: 1295-9.
39. Bradford, P.A. (2001) Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14: 933-51, table of contents.
40. Hasman, H. and Aarestrup, F.M. (2005). tcrB, a gene conferring transferable copper resistance in Enterococcus faecium: occurrence, transferability, and linkage to macrolide and glycopeptides resistance. Antimicrob. Agents Chemother. 46: 1410-6.
41. Liebana, E., Batchelor, M., Hopkins, K.L., et al. (2006). Longitudinal farm study of extended-spectrum betalactamase-mediated resistance. J. Clin. Microbiol. 44: 1630-4.
42. Riano, I., Moreno, M.A., Teshager, T., Saenz, Y., Dominguez, L. and Torres, C. (2006). Detection and characterization of extended-spectrum {beta}-lactamases in Salmonella enterica strains of healthy food animals in Spain. J. Antimicrob. Chemother. 58: 844-7.
43. Weill, F.X., Lailler, R., Praud, K., et al. (2004). Emergence of extended-spectrum-beta-lactamase (CTX-M-9)-producing multiresistant strains of Salmonella enterica serotype Virchow in poultry and humans in France. J. Clin. Microbiol. 42: 5767-73.
44. Carattoli, A. Lovari, S., Franco, A., Cordaro, G., Di Matteo, P. and Battisti, A. (2005). Extended-spectrum betalactamases in Escherichia coli isolated from dogs and cats in Rome, Italy, from 2001 to 2003. Antimicrob. Agents Chemother. 49(2): 833-5.
45. Feria, C., Ferreira, E., Correia, J.D., Goncalves, J. and Canica, M. (2002). Patterns and mechanisms of resistance to beta-lactams and beta-lactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal. J. Antimicrob. Chemother. 49: 77-85.
46. Sidjabat, H.E., Hanson, N.D., Smith-Moland, E., et al. (2007). Identification of plasmamid-mediated extended-spectrum and AmpC beta-lactamases in Enterobacter spp. isolated from dogs. J. Med. Medicrobiol. 56: 426-34.
47. Blondeau, J.M., Zhao, X., Hanson, G. and Drlica, K. (2001). Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 433-8.
48. Catry, B., Laevens, H., Devriese, L.A. Opsomer, G. and De Kruif, A. (2003). Antimicrobial resistance in livestock. J. Vet. Pharmacol. Ther. 26: 81-93.
49. Drlica, K., Zhao, X., Blondeau, J.M. and Hesje, C. (2006). Low correlation between MIC and mutant prevention concentration. Antimicrob. Agents Chemother. 50: 403-404.
50. Balaban, N.Q., Merrin, J., Chait, R., Kowalik, L. and Leibler, S. (2004). Bacterial persistence as a phenotypic switch. Science 305: 1622-5.
51. Keren, I., Kaldalu, N., Spoering, A., Wang, Y. and Lewis, K. (2004). Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230: 13-18.
52. Levin, B.R. and Rozen, D.E. (2006). Non-inherited antibiotic resistance. Nat. Rev. Microbiol. 4: 556-62.
53. Wiuff, C., Zappala, R.M., Regoes, R.R., Garner, K.N., Baquero, F. and Levin, B.R. (2005). Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob. Agents Chemother. 49: 1483-94.
54. AliAbadi, F.S. and Lees, P. (2001). Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration. Am. J. Vet. Res. 62: 1979-89.
55. AliAbadi, F.S. and Lees, P. (2002). Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. J. Vet. Pharmacol. Ther. 25: 161-174.
56. AliAbadi, F.S. and Lees, P. (2003). Pharmacokinetic-pharmacodynamic integration of danofloxacin in the calf. Res. Vet. Sci. 74: 247-59.
57. Aliabadi, F.S., Badrelin, H. Ali, Landoni, M.F. and Lees, P. (2003a). Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids. Vet. J. 165: 104-18.
58. AliAbadi, F.S., Landoni, M.F. and Lees, P. (2003b). Pharmacokinetics (PK) pharmacodynamics (PD) and PK-PD integration of danofloxacin in sheep biological fluids. Antimicrob. Agents Chemother. 47: 626-35.
59. Koritz, G.D., Kilroy, C.R. and Bevill, R.F. (1994). Pharmacokinetics-pharmacodynamic modelling of antibacterial therapy in vitro. In Proceedings of the 6th International Congress of the European Association for Veterinary Pharmacology and Therapeutics. Edinburgh, UK, Blackwell Scientific Publications.
60. Yancey, Jr., R.J., Evans, R.A., Kratzer, D.D. Paulissen, J.B. and Carmer, S.G. (1990). Efficacy of ceftiofur hydrochloride for treatment of experimentally induced colibacillosis in neonatal swine. Am. J. Vet. Res. 51: 831-47.
61. Dalhoff, A. and Shalit, I. (2003). Immunomodulatory effects of quinolones. Lancet Infect. Dis. 3: 359-71.
62. Hoyt, J.C. and Robbins, R.A. (2001).Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol. Lett. 205: 1-7.
63. Ianaro, A., Ialenti, A., Maffia, P., et al. (2000). Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. Exp. Ther. 292: 156-63.
64. Lindecrona, R.H., Friis, C. and Nielsen, J.P. (2000). Pharmacokinetics and penetration of danofloxacin into the gastrointestinal tract in healthy and inSalmonella typhimurium infected pigs. Res. Vet. Sci. 68: 211-6.
65. Lees, P. and AliAbadi, F.S. (2000). Rationalising dosage regimens of antimicrobial drugs; a pharmacological perspective. J. Med. Microbiol. 49: 943-5.
66. Lees, P. and AliAbadi, F.S. (2002). Rational dosing of antimicrobial drugs; animals versus humans. Int. J. Antimicrob. Agents 19: 269-84.
67. McKellar, Q.A., Sanchez Bruni, S.F. and Jones, D.G. (2004). Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J. Vet. Pharmacol. Ther. 27: 503-14.
68. Mouton, J.W., Dudley, M.N., Cars, O., Derendorf, H. and Drusano, G.L. (2002). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for antiinfective drugs. Int. J. Antimicrob. Agents 19: 355-8.
69. Toutain, P.L. (2002). Pharmacokinetics/pharmacodynamics integration in drug development and dosage regimen optimisation for veterinary medicine. AAPS Pharmaceuti. Sci. 4: 1-25, article
70. Toutain, P.L. (2003a). Pharmacokinetics/pharmacodynamics integration in dosage regimen optimisation for veterinary medicine. J. Vet. Pharmacol. Ther. 26 (Suppl 1): 1-8.
71. Toutain, P.L. (2003b). Antibiotic treatment of animals-a different approach to rational dosing. Vet. J. 165: 98-100.
72. Toutain, P.L., del Castillo, J.R. and Bousquet-Melou, A. (2002). The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Res. Vet. Sci. 73: 105-14.
73. Craig, W.A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26: 1-12.
74. Drusano, G.L., Johnson, D.E., Rosen, M. and Standiford, H.C. (1993). Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37: 483-90.
75. Schentag, J.J. (2000). Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin. Infect. Dis. Suppl. 2: 540-544.
76. Sarasola, P., Lees, P., AliAbadi, F.S., et al. (2002). Pharmacokinetic and pharmacodynamic profiles of danofloxacin administered by two dosing regimens in calves infected with Mannheimia (Pasteurella) haemolytica. Antimicrob. Agents Chemother. 46: 3013-9.
77. Blaser, J., Stone, B.B., Groner, M.C. and Zinner, S.H. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentrations to MIC for bacterial activity and emergence of resistance. Antimicrob. Agents Chemother. 31: 1054-60.
78. Marchbanks, C.R., McKiel, J.R., Gilbert, D.H., et al. (1993). Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob. Agents Chemother. 37: 1756-63.
79. Bugyei, K., Black, W.D. and McEwen, S. (1999). Pharmacokinetics of enrofloxacin given by the oral, intravenous and intramuscular routes in broiler chickens. Can. J. Vet. Res. 63: 193-200.
80. Ding, H.Z., Zeng, Z.L., Fung, K.F., Chen, Z.L. and Qiao, G.L. (2001). Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications. J. Vet. Pharmacol. Ther. 24: 303-308.
81. Fernandez-Varon, E., Bovaira, M.J., Espuny, A., Escudero, E., Vancraeynest, D. and Carceles, C.M. (2005). Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. J. Vet. Pharmacol. Ther. 28: 343-8.
82. Intorre, L., Mengozzi, G., Bertini, S., Bagliacca, M., Luchetti, E. and Soldani, G. (1997). The plasma kinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Muscovy duck. Vet. Res. Commun. 21: 127-36.
83. Wiuff, C., Lykkesfeldt, J., Svendsen, O. and Aarestrup, F.M. (2003). The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs. Res. Vet. Sci. 75: 185-93.
84. Fernandez-Varon, E., Ayala, I., Marin, P., et al. (2006). Pharmacokinetics of danofloxacin in horses after intravenous, intramuscular and intragastric administration. Equine Vet. J. 38: 342-6.
85. Giles, C.J., Magonigle, R.A., Grimshaw, W.T., et al. (1991). Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J. Vet. Pharmacol. Ther. 14: 400-10.
86. Barker, C.W., Zhang, W., Sanchez, S., Budsberg, S.C., Boudinot, F.D. and McCrackin Stevenson, M.A. (2003). Pharmacokinetics of imipenem in dogs. Am. J. Vet. Res. 64: 694-9.
87. Bidgood, T. and Papich, M.G. (2002). Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs. Am. J. Vet. Res. 63: 1622-8.
88. Guyonnet, J., Monnoyer, S., Manco, B., Aliabadi, F.S. and Lees, P. (2003). In vivo pharmacokinetics and in vitro pharmacodynamics as a basis for predicting dosage of colistin in piglet g.i.t. disease. J. Vet. Pharmacol. Ther. 26 Suppl. 1: 148-9.
89. Lees, P., Aliabadi F.S. and Toutain, P-L. (2004). PK-PD modelling: an alternative to dose titration studies for antimicrobial drug dosage selection. J. Reg. Affairs 15: 175-80.
90. Toutain, P.L. and Lees, P. (2004). Integration and modelling of pharmacokinetic and pharmacodynamic data to optimise dosage regimens in veterinary medicine. J. Vet. Pharmacol. Ther. 27: 467-77.
91. Drusano, G.L. (2004). Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2: 289-300.
92. Mouton, J.W. (2005). Impact of pharmacodynamics on dosing schedules: optimising efficacy, reducing resistance, and detection of emergence of resistance. In Antibiotic Policies Theory and Practice (Eds. Gould, I.M. and van der Meer, J.W.M.). Kluwer Academic/Plenum Publishers, New York, pp. 387-407.
93. Mazzei, T. and Novelli, A. (1999). How macrolide pharmacodynamics affect bacterial killing. Infect. Med. 16: 22-8.
94. Benchaoui, H.A., Nowakowski, M., Sheripngton, J., Rowan, T.G. and Sunderland, S.J. (2004). Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J. Vet. Pharmacol. Ther. 27: 203-10.
95. Nowakowski, M.A., Inskeep, P.B., Risk, J.E., et al. (2004). Pharmacokinetics and lung tissue concentrations of tulathromycin, a new triamilide antibiotic, in cattle. Vet. Ther. 5: 60-74.
96. Goswami, S.K., Kivity, S. and Marom, Z. (1990). Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am. Rev. Resp. Dis. 141: 72-8.
97. Morikawa, K., Oseko, F., Morikawa, S. and Iwamoto, K. (1994). Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob. Agents Chemother. 38: 2643-7.
98. Roche, Y., Gougerot-Pocidalo, M.A., Fay, M., Forest, N. and Pocidalo, J.J. (1986). Macrolides and immunity: effects of erythromycin and spiramycin on human mononuclear cell proliferation. J. Antimicrob. Chemother. 17: 195-203.
99. Takeyama, K., Tamaoki, J., Chiyotani, A., Tagaya, E. and Konno, K. (1993). Effect of macrolide antibiotics on ciliary motility in rabbit airway epithelium in vitro. J. Pharm. Pharmacol. 45: 756-8.
100. Takizawa, H., Desaki, M., Ohtoshi, T., et al. (1995). Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem. Biophys. Res. Comm. 210: 781-6.
101. Tamaoki, J., Noritaka, S., Tagaya, E. and Konno, K. (1994). Macrolide antibiotics protect against endotoxin-induced vascular leakage and neutrophil accumulation in rat trachea. Antimicrob. Agents Chemother. 38: 1641-3.
102. Umeki, S. (1993). Anti-inflammatory action of erythromycin: its inhibitory effect on neutrophil NADPH oxidase activity. Chest 104: 1191-1193.
103. Delissalde, F. and Amabile-Cuevas, C.F. (2004). Comparison of antibiotic susceptibility and plasmid content, between biofilm producing and non-producing clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents. 24: 405-8.
104. Drenkard, E. and Ausubel, F.M. (2002). Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416: 740-3.
105. Gilbert, P., McBain, A. and Rickard, A.H. (2003). Biofilms and bacterial multi-resistance. In Multiple Drug Resistant Bacteria (ed. Amabile-Cuevas, C.F.). Horizon Scientific Press, Wymondham.
106. Oliver, A., Canton, R., Campo, P., Baquero, F. and Blazquez, J. (2000). High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288: 1251-3.
107. Preston, S.L., Drusano, G.L., Berman, A.L., et al. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. J. Am. Med. Assoc. 279: 125-9.
108. Thorburn, C.E. and Edwards, D.I. (2001). The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. J. Antimicrob. Chemother. 48: 15-22.
109. Michae-Hamzehpour, M., Auckenthaler, R., Regamey, P. and Pechere, J.C. (1987). Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob. Agents Chemother. 31: 1803-1808.
110. Thomas, J.K., Forrest, A., Bhaveni, S.M., et al. (1998). Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42: 521-7.
111. Forrest, A., Nix, D.E., Ballow, C.H., Goss, T.F., Birmingham, M.C. and Schentag, J.J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37: 1073-81.
112. Firsov, A.A., Vostrov, S.N. Lubenko, I.Y., Drlica, K., Portnoy, Y.A. and Zinner, S.H. (2003). In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1604-13.
113. Tam, V.H., Louie, A., Deziel, M.R., Liu, W., Leary, R. and Drusano, G.L. (2005a). Bacterial-population responses to drug-selective pressure: examination of Garenoxacin's effect on Pseudomonas aeruginosa. J. Infect. Dis. 192: 420-8.
114. Jumbe, N., Louie, A., Leary, R., et al. (2003). Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112: 275-85.
115. Charleston, B., Gate, J.J., Aitken, I.A., Stephan, B. and Froyman, R. (1998). Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or polsed-water medication against Escherichia coli infection in chickens. Antimicrob. Agents Chemother. 42: 83-7.
116. Moore, R.D., Smith, C.R. and Lietman, P.S. (1984). Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am. J. Med. 77: 657-62.
117. Stearne, L.E., Lemmens, N., Goessens, W.H.F., Mouton, J.W. and Gyssens, I.C. (2002). In European Conference Clinical Microbiology and Infectious Diseases, Milan.
118. Odenholt, I., Gustafsson, I., Lowdin, E. and Cars, O. (2003). Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob. Agents Chemother. 47: 518-23.
119. Tam, V.H., Schilling, A.N., Neshat, S., Poole, K., Melnick, D.A. and Coyle, E.A. (2005b). Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 4920-7.
120. Lees, P., Concordet, D., Aliabadi, F.S. and Toutain, P.-L. (2006). Drug selection and optimization of dosage schedules to minimize antimicrobial resistance. In Antimicrobial Resistance in Bacteria of Animal Origin (ed. Frank, M.). Aerestrup, ASM Press, Washington, D.C. pp. 49-71.
121. Regnier, A., Concordet, D., Schneider, M., Boisrame, B. and Toutain, P.L. (2003). Population pharmacokinetics of marbofloxacin in the aqueous humour after intravenous administration in dogs. Am. J. Vet. Res. 64: 889-93.
122. del Castillo, J.R., Laroute, V., Pommier, P., et al. (2006). Interindividual variability in plasma concentrations after systemic exposure of swine to dietary doxycycline supplied with and without paracetamol: a population pharmacokinetic approach. J. Anim. Sci. 84: 3155-66.
123. Riond, J.L. and Riviere, J.E. (1989). Effects of tetracyclines on the kidney in cattle and dogs. J. Am. Vet. Med. Assoc. 195: 995-7.
124. MacGowan, A.P. (2004). Elements of design: the knowledge on which we build. Clin. Microbiol. Infect. 10 Suppl 2: 6-11.